Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

<p>Abstract</p> <p>Background</p> <p>P276-00 is a novel cyclin-dependent kinase inhibitor currently in Phase II clinical trials. Gemcitabine is a standard of care for the treatment of pancreatic cancer. The present study investigated the effect of the combination of P27...

Full description

Bibliographic Details
Main Authors: Rathos Maggie J, Joshi Kavita, Khanwalkar Harshal, Manohar Sonal M, Joshi Kalpana S
Format: Article
Language:English
Published: BMC 2012-08-01
Series:Journal of Translational Medicine
Subjects:
Cdk inhibitor
P276-00
Gemcitabine
Combination studies
Pancreatic cancer
Online Access:http://www.translational-medicine.com/content/10/1/161

Internet

http://www.translational-medicine.com/content/10/1/161

Similar Items